MedTrace Logo

Tranexamic Acid Reduce Blood Loss in Meningioma Resection

NCT04386642 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-01-27

No results posted yet for this study

Summary

In neurosurgical setting, a large sample size trials of tranexamic acid (TXA) has been limited to TBI and SAH.

The evidence of TXA in brain tumor was scarce. A few case reports support the role of TXA in brain tumor patients with significant intraoperative bleeding and difficult achieving hemostasis. To prove the benefit of TXA for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required. This prospective, randomized double-blind controlled study will be conducted to evaluate the effect of TXA in reducing blood loss and blood transfusion in patients with intracranial meningiomas, diameter \> 5 cm in at least 2 dimensions from the latest radiographic findings.

Conditions

  • Meningioma

Interventions

DRUG

Tranexamic acid

Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.

DRUG

Placebo

normal saline solution in a clear 50-ml syringe

Sponsors & Collaborators

  • Chiang Mai University

    lead OTHER

Principal Investigators

  • Pathomporn Pin-on, MD · Chiang Mai University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-07-31
Completion
2022-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04386642 on ClinicalTrials.gov